SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress
August 12, 2015 06:30 ET
|
SAGE Therapeutics
Global Phase 3 STATUS Trial to Evaluate SAGE-547 as a Treatment for SRSE Now Open for Enrollment
Novel, Proprietary Second-Generation Product Candidates Poised to Enter Phase 1 in...
SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
August 06, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE) today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol...
SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
August 05, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
June 09, 2015 06:30 ET
|
SAGE Therapeutics
Marked Improvement Demonstrated in HAM-D Scores in Patients with PPD Enrolled in Open-Label Trial
Plan to Initiate Placebo-Controlled Trial of SAGE-547 by Year End and Advance Novel Product...
SAGE Therapeutics to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference
June 03, 2015 06:00 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
May 14, 2015 06:30 ET
|
SAGE Therapeutics
SAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE...
SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
May 14, 2015 06:15 ET
|
SAGE Therapeutics
SAGE-547 Demonstrates Favorable Tolerability
Pharmacodynamic Activity Corroborated by Continuous EEG Findings
Phase 3 STATUS Trial Expected to Initiate by Mid-2015
Conference Call Scheduled...
SAGE Therapeutics to Present at UBS Global Healthcare Conference
May 12, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceuticals company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
May 07, 2015 16:00 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous...
SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
April 21, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced the closing of its previously announced underwritten public offering of common stock, including the...